26 results about "Bone marrow sample" patented technology

The invention provides a microscopic image-based cell classification method and a blood disease identification and verification cloud platform system, and relates to the field of hematopoietic system detection, the system comprises a terminal AI processing system, a central server AI processing system and an on-demand interaction system, and the terminal AI processing system and the central server AI processing system jointly construct a two-stage intelligent identification system architecture. Through the cooperation of the above structures, the system has the following beneficial effects: 1, a two-stage AI frame is adopted, data congestion is reduced, the workload of a central server is reduced, and in addition, only necessary data is uploaded through segmented transmission of images and an on-demand interaction mechanism, so that the data transmission amount is reduced; 2, a deep learning technology is utilized to realize automatic analysis of blood cell sample and bone marrow sample images; and thirdly, a feedback mechanism is introduced, and a set of intelligent verification system for continuous learning and optimization is constructed through mutual fusion of professional experience of doctors and an advanced deep learning technology.

The invention relates to the technical field of stem cells, in particular to a mesenchymal stem cell separation and culture method based on real-time monitoring. The method comprises the following steps: S1, collecting a bone marrow sample; step S2, primary separation; s3, carrying out enzyme digestion; step S4, carrying out secondary separation; and S5, changing the liquid. According to the method, due to the fact that the first-time liquid changing time has a certain influence on reproduction and growth of the mesenchymal stem cells, the separation quality is guaranteed and the separation efficiency is improved by monitoring the key step, namely liquid changing, of the adherent method in real time, refining the liquid changing time and accurately determining the first-time liquid changing time, and meanwhile the separation efficiency is improved. A camera device and an image processing technology are adopted, the color change and bubble state of a culture solution are monitored in real time, culture conditions are adjusted in time, it is ensured that the growth environment of cells is appropriate, through an automatic monitoring and feedback mechanism, the requirement for manual intervention is reduced, and operation simplicity and reliability are improved; the separation and culture efficiency of the mesenchymal stem cells is improved.

The invention provides a use of a marker or a combination thereof in preparation of a product for prediction, diagnosis or auxiliary diagnosis of measurable residual diseases, the measurable residual diseases occur after clinical complete remission of acute myelogenous leukemia patients, and the marker or the combination thereof comprises a C-X-C chemokine receptor 4 gene. According to the method, a multi-parameter flow sorting technology is adopted, leukemia cell populations are separated from bone marrow samples of patients in the first diagnosis stage and the AML MRD stage, and a sufficient number of residual disease cells are successfully captured through a single cell transcriptome sequencing technology. The CXCR4 low-expression cell is identified to be capable of being used as a common marker of an MRD cell, and is verified in a clinical AML patient specimen. And an innovative scheme is provided for MRD monitoring of AML patients lacking clear molecular markers. And meanwhile, a CXCR4 low-expression cell is provided as a function substitution model of the MRD cell, so that the technical limitation of insufficient residual cells in the traditional research is broken through, and a reliable research system is established for systematically exploring the biological characteristics of the MRD cell.

The present invention refers to an in vitro method to determine simultaneously anti-cancer activity and hematotoxicity of an antibody-drug conjugate, comprising: (a) mixing a sample comprising cancer cells with a bone marrow sample; (b) adding an antibody-drug conjugate to the mixture of step (a); (c) determining anti-cancer activity of the antibody-drug conjugate by measuring cell depletion of tumor cells; and (d) determining hematotoxicity of the antibody-drug conjugate by measuring cell depletion of cells of the bone marrow sample.

There are provided methods for detecting and classifying a B-cell malignancy selected from the group consisting of a B-cell lymphoma, a B-cell leukemia, and a plasma cell dyscrasia in a subject. The methods employ a tumor cell profiling algorithm to analyze single-cell RNA sequencing data obtained from a sample of, e.g., the subject's blood or bone marrow, enriched for a cell type comprising tumoral cells using a cell surface marker. This algorithm identifies one or more one or more expanded clonal cell populations and categorizes each of the one or more expanded clonal cell populations as malignant or pre-malignant tumor cell population if expression of one or more malignancy markers is detected. The one or more malignant or pre-malignant tumor cell population(s) can be analyzed using a statistical model or machine learning algorithm to classify the B-cell malignancy.

To provide methods for preparing compositions enriched in T regulatory cells (Tregs) and methods for treating immunological diseases using the compositions, and to provide methods for preparing compositions enriched in lymphocytes and depleted of Tregs and use of the compositions in treating proliferative diseases.SOLUTION: A method for preparing a composition enriched in CD4+CD25hi T regulatory cells (Tregs) is provided, comprising contacting in vitro a population of human cells including T lymphocytes obtained from a patient-derived human blood or bone marrow sample with a tumor necrotic factor receptor 2 (TNFR2) agonist or an NF-κB activator, thereby preparing the composition in which the Tregs are enriched, wherein the Tregs constitute at least 60% of the cells in the composition.SELECTED DRAWING: None

The invention discloses a method for detecting 19 amino acids in brain tissue and bone marrow of a mouse. The method comprises the following steps: step 1, preparing a standard substance; step 2, sampling brain tissues and bone marrow of the mouse; step 3, removing proteins in brain tissues and bone marrow samples; step 4, preparing a derivatization reagent; step 5, separating and determining 19 amino acids in the brain tissue and the bone marrow sample by HPLC-FLD; and 6, calculating a result. The method for detecting 19 amino acids in brain tissues and bone marrow of mice has the advantages of simple operation steps, high accuracy and good sensitivity, and can realize accurate detection of 19 amino acids in brain tissues and bone marrow samples.

The invention relates to a kit for assisting POEMS syndrome diagnosis and a POEMS syndrome evaluation system. The kit comprises a reagent for quantitatively detecting the expression level of one or more genes in CLIC4, FCHSD2, FNDC3A, IKZF1 and TIMP2, an RNA extraction reagent and / or an adulterated gene. The kit is used for detecting the expression level of one or more genes in CLIC4, FCHSD2, FNDC3A, IKZF1 and TIMP2 in a bone marrow sample of a patient, and whether the patient has the POEMS syndrome or not is comprehensively judged by combining the clinical characteristics of the kit. The POEMS syndrome evaluation system comprises a data acquisition module and an evaluation module and is used for evaluating the POEMS syndrome in combination with clinical characteristics of a patient and the expression level of a target gene, and compared with existing diagnosis only depending on the clinical characteristics, the evaluation system can assist in diagnosis of the POEMS syndrome from the molecular level, so that the diagnosis efficiency is improved. And the situation that false positive or false negative easily occurs when the POEMS syndrome is diagnosed only by clinical characteristics at present is reduced.

The present disclosure relates to computer-implemented methods for classifying cell neighborhoods in a bone marrow sample obtained from a subject suffering from multiple myeloma (MM) and for defining significant cell neighborhoods in that sample that are associated with treatment outcomes in subjects with MM who receive a T cell-redirecting therapy. Image processing systems that can be used to analyze bone marrow samples and identify cell neighborhoods are also provided. Moreover, methods for predicting a treatment response to a T cell-redirecting therapy in a subject suffering from MM are disclosed.

This utility model discloses a bone aspiration sampling needle, belonging to the field of medical devices. One end of the outer needle body is serrated, and an axial sample receiving cavity is provided inside the outer needle. One end of the inner needle body is equipped with a drill bit. The inner needle body is detachably fitted into the sample receiving cavity, with the drill bit extending out of the serrated end of the sample receiving cavity. The outer wall of the inner needle body fits against the inner wall of the serrations. After the drill bit penetrates the cortical bone of the lesion, the inner needle is withdrawn, and only the outer needle advances. During the advancement of the outer needle, the serrations cut the bone marrow, and the cut bone marrow enters the sample receiving cavity. The outer needle is withdrawn, and the bone marrow sample is extracted, preserving the original appearance and structure of the bone marrow sample. A drainage connector is also provided. The outer needle is connected to a flushing device through the drainage connector, allowing for the injection of medication to treat and flush the bone lesion, or for the extraction of diseased bone marrow and waste fluid through a drainage device. The sample receiving cavity can also be cleaned through the drainage connector.

The invention discloses a bone marrow sample filtering device, a sample tube and a filtering method, and relates to the technical field of medical instruments.The bone marrow sample filtering device comprises an annular filtering frame and a filtering layer, and the outer side wall of the annular filtering frame can be in sealed contact with the inner side wall of the sample tube; the annular filter frame can axially move in the sample tube along the sample tube; the filter layer is fixedly arranged on the inner side of the annular filter frame, can shield the inner side space of the annular filter frame, and is matched with the annular filter frame to divide the interior of the sample pipe into an upper layer and a lower layer, so that the bone marrow sample solution is filtered. According to the bone marrow sample filtering device, the sample tube and the filtering method provided by the invention, the bone marrow sample filtering time is short, the efficiency is high, the operation is simple and convenient, and sample pollution is not easily caused.

The invention provides a primer probe group for detecting three leukemia fusion genes BCR-ABL1, ETV6-RUNX1 and TCF3-PBX1 and application of the primer probe group, and establishes a method for simultaneously detecting RNA of the three fusion genes based on capture and ligation reaction combined with multiple fluorescent quantitative PCR. The primer probe group comprises a capture probe, a connection probe, an amplification primer and a Taq-Man probe which are respectively used for detecting multiple types and reference genes of three fusion genes. Nucleic acid extraction and reverse transcription are not needed, target RNA in whole blood, dried blood spots or bone marrow samples can be directly split and captured, and three fusion genes are simultaneously detected in the same fluorescent quantitative PCR reaction system. The detection sensitivity is that the copy / reaction of BCR-ABL1 is 75, the copy / reaction of ETV6-RUNX1 is 6, and the copy / reaction of TCF3-PBX1 is 29.

The embodiment of the invention provides a method for determining children refractory ITP pathogenesis, at least part of pathogenesis of RITP is determined, and the method comprises the following steps: S1, collecting a bone marrow sample; s2, carrying out sequencing treatment by utilizing the bone marrow sample; the sequencing treatment comprises single cell transcriptome sequencing; s3, obtaining cell type information of RITP and CITP according to a sequencing result; s4, comparing the cell type information of RITP and CITP, and determining the main destroying cell type causing immune destruction to the target cell in the multiple cell types of intractable ITP; s5, performing communication interaction analysis by using the bone marrow sample, and constructing a first cell communication network and a second cell communication network corresponding to the RITP and the CITP respectively; s6, comparing the first cell communication network with the second cell communication network, and determining a receptor which is not included in the second cell communication network in the first cell communication network as an undetermined receptor; and S7, determining the specific receptor between the main destroyed cell type of the RITP and the target cell according to the expression condition of the to-be-determined receptor in the first cell communication network.

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

This application discloses a method, apparatus, device, and storage medium for determining pathological indicators. The method includes: acquiring a bone marrow pathological image to be processed; preprocessing the bone marrow pathological image to obtain a set of bone marrow sample images; processing the set of bone marrow sample images to obtain a bone marrow tissue region image; processing the bone marrow tissue region image to determine the bone marrow adipose tissue region and trabecular bone tissue region, removing the bone marrow adipose tissue region and trabecular bone tissue region to obtain a processed bone marrow tissue image; inputting the processed bone marrow tissue image into a trained image segmentation model to obtain the bone marrow fibrous region; and statistically analyzing the degree of fibrosis based on the bone marrow tissue region image and the bone marrow fibrous region to determine pathological indicators. This method can extract the layout details of the pathological image, thereby enabling a more comprehensive and fine-grained statistical analysis of the degree of fibrosis and improving the accuracy of pathological indicator determination.

This invention relates to a method and system for analyzing complex cytokine exosomes in bone marrow and blood from elderly patients with hip fractures. The method includes bone marrow sample collection (predicting the degree of fibrosis and adjusting the collection volume), pretreatment (optimizing sample composition), dynamic gradient bone marrow digestion (adjusting enzyme ratios according to the fibrosis index and monitoring in multiple dimensions), exosome extraction (ultracentrifugation and nanofiltration), and complex cytokine exosome analysis (constructing a seven-dimensional matrix, etc.). The system consists of units for bone marrow sample collection, pretreatment, dynamic gradient bone marrow digestion, exosome extraction, and complex cytokine exosome analysis. This invention solves the problems of exosome damage and low separation efficiency in traditional methods, and has advantages such as increased exosome extraction volume, preservation of integrity, enhanced reliability of analytical results, and improved standardization and reproducibility.

The invention discloses an integrated bone marrow sample treatment device which comprises a flow guide plate, the flow guide plate is integrally in a semi-arc shape and is integrally designed from top to bottom, arc-shaped plates are integrally formed on the two sides of the flow guide plate respectively, the curvature of the arc-shaped plates is larger than that of the flow guide plate, and the curvature of the arc-shaped plates is larger than that of the flow guide plate. The arc-shaped plate is gradually designed to be in an involute shape from top to bottom, a collecting barrel is installed at the bottom end of the flow guide plate, and a plurality of arc-shaped baffles are sequentially installed on the inner wall face of the flow guide plate at equal intervals from top to bottom. By arranging the flow guide plate, the arc-shaped plate, the arc-shaped baffle, the A-section arc-shaped surface and the B-section arc-shaped surface, mutual cooperation is utilized, and a marrow sample is synchronously poured along with sterile water, so that the sample concentration can be diluted, the mobility of the sample is improved, and the separation effect of crushed bone impurities and the marrow sample is assisted to be improved; therefore, the working process of integrated screening and diluting treatment of the bone marrow sample is completed, and the practicability of the device is further improved.

The invention discloses an acute myelogenous leukemia first treatment course curative effect diagnosis model and a construction method and application thereof.The prognosis model is an acute myelogenous leukemia prognosis model based on eight clinical characteristics, and the construction method comprises the steps that clinical data from a patient in a dataset and RNA sequencing data of peripheral blood and bone marrow samples are combined with survival information to obtain a first treatment course curative effect diagnosis model of acute myelogenous leukemia; the method comprises the following steps: sequentially carrying out single-variable logistic regression analysis and multivariable logistic regression analysis on the basis of a single-variable logistic regression model, further weighting an expression level according to an obtained regression coefficient, and establishing a first treatment course curative effect diagnosis model of acute myelogenous leukemia based on eight clinical characteristics. The acute myelogenous leukemia first treatment course curative effect diagnosis model has a good evaluation effect.

The invention relates to a bone marrow blood composite cell factor exosome analysis method and system for hip fracture of old people. The method comprises the steps of bone marrow sample collection (pre-judging the fibrosis degree and adjusting the collection amount), pretreatment (optimizing sample composition), dynamic gradient bone marrow digestion (adjusting the enzyme proportion according to the fibrosis index and performing multi-dimensional monitoring), exosome extraction (ultracentrifugation and nanofiltration) and composite cell factor exosome analysis (constructing a seven-dimensional matrix and the like). The system is composed of a bone marrow sample collection unit, a pretreatment unit, a dynamic gradient bone marrow digestion unit, an exosome extraction unit and a composite cell factor exosome analysis unit. The method solves the problems of exosome damage and low separation efficiency of a traditional method, and has the advantages that the exosome extraction amount is increased, the integrity is protected, the reliability of an analysis result is enhanced, and the standardization and repeatability are improved.

The invention discloses an LOX targeted intervention method for treating idiopathic thrombocythemia, and relates to the technical field of medicine and health, and the LOX targeted intervention method comprises the following steps: detecting the LOX expression level of a patient, collecting a peripheral blood or bone marrow sample of an ET patient, detecting the mRNA expression level of LOX through real-time fluorescent quantitative PCR, screening a patient with high LOX expression, applying an LOX specific inhibitor, and giving the LOX inhibitor to the patient with high LOX expression. By means of individualized treatment of LOX expression layering, accurate intervention of patients with high LOX expression is achieved, the problem that at present, the effect of LOX in the ET disease pathogenesis is not clear is solved, deep understanding of the ET pathogenesis is facilitated, and a theoretical basis is provided for subsequent targeted treatment.

The invention relates to the technical field of medicines, and provides application of zalcitabine in drugs for inhibiting and / or preventing and / or relieving and / or treating multiple myeloma in order to solve the problems that whether zalcitabine has anti-tumor activity in MM and related molecular mechanisms are not clear at present. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or relieving and / or treating multiple myeloma. The pharmaceutical preparation comprises an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is 2 ', 3'-dideoxycytidine. Researches show that zalcitabine induces mitochondrial dysfunction by targeted inhibition of expression of TFAM, and induces occurrence of ferroptosis of MM cells by triggering a cGAS-STING pathway through mtDNA cytoplasm stress. In-vivo animal experiments further show that zalcitabine can significantly slow down tumor growth. In addition, the antineoplastic activity of zalcitabine is also verified in a bone marrow sample derived from an MM patient.

Methods of predicting relapse in a patient post HSCT, and methods of treatment, the methods including obtaining a bone marrow sample from the patient post- transplantation; and determining TCR clonal diversity of a population of T cells within the bone marrow sample; wherein TCR clonal diversity is indicative of risk of relapse.

The invention discloses application of OPTN in treatment of NPM1 mutant leukemia, and relates to the technical field of biological medicines. Comprising application of OPTN as a biomarker in preparation of a prognosis evaluation product of NPM1 mutation AML. The evaluation product is a kit, and the kit comprises an OPTN gene probe or an anti-OPTN antibody. The kit is used for quantifying the OPTN mRNA or protein level in a bone marrow sample. According to the scheme provided by the invention, the OPTN is highly expressed in the NPM1 mutation AML and is related to poor prognosis, so that the OPTN becomes an ideal treatment target; by inhibiting the OPTN, the mitochondrial autophagy pathway can be accurately blocked, the drug resistance of leukemia cells is reduced, and normal cells are not influenced.

Provided herein are methods and immune biomarkers that identify progression and treatment options for hematological malignancies (e.g., smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), or multiple myeloma (MM)). Also provided are materials and methods for the prognosis, staging, and monitoring of SMM, MGUS, or MM based on the presence of the immune biomarkers in a sample (e.g., a blood sample or a bone marrow sample), as well as methods for monitoring the progression of SMM, MGUS, or MM, determining the efficacy of a therapeutic agent, determining a treatment for SMM, MGUS (e.g., before progression to MM), or MM, and / or treating SMM, MGUS, or MM. The methods provided herein provide several advantages over invasive biopsies.

The utility model provides a bone marrow sample long-term low-temperature storage auxiliary device which comprises a liquid nitrogen tank body, a liquid nitrogen tank neck is fixedly installed on the top of the liquid nitrogen tank body, a sealing structure is arranged in the liquid nitrogen tank neck, a plurality of hanging grooves are formed in the inner wall of the liquid nitrogen tank neck, and a bone marrow sample storage structure is arranged between the hanging grooves and the liquid nitrogen tank body. By designing the bone marrow sample storage structure, when the bone marrow sample storage box is used and the bone marrow samples are stored, the sealed bone marrow samples can be placed in the bone marrow sample storage box, the sliding block slides to the center of the connecting plate along the sliding groove, and then the connecting plate is placed in the tank body of the liquid nitrogen tank along the tank neck of the liquid nitrogen tank; after the connecting plate is placed in the liquid nitrogen tank body, due to lack of external pressure, the sliding block can move to the end of the connecting plate along the sliding groove under the reverse elastic force of the pressure spring, so that the redundant space of the liquid nitrogen tank body is occupied, and the space utilization rate of the liquid nitrogen tank body is increased.

The invention belongs to the field of biological pharmacy, and particularly discloses application of long-chain non-coding RNA lncRNA ALLHET (the sequence is shown as SEQ ID NO: 1) in diagnosis, treatment and prognosis evaluation of acute lymphocytic leukemia (ALL). The ALLHET expression quantity in a bone marrow sample is detected through qRT-PCR (Quantitative Reverse Transcription-Polymerase Chain Reaction) (primers are as shown in SEQ ID NO: 2-3), and the ALLHET expression quantity can be used as an ALL diagnostic marker after being obviously Prognostic analysis based on expression level grouping shows that the event-free survival rate (EFS) of a high expression group is remarkably reduced. Meanwhile, the ALLHET inhibitor can effectively inhibit ALL cell proliferation, promote apoptosis and block the cell cycle, and obviously inhibit tumor growth in an animal model. The invention provides a novel diagnostic target, a therapeutic drug and a prognosis evaluation system for ALL.